{"id":"sfp","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL3833317","moleculeType":"Small molecule","molecularWeight":"1321.57"},"_dailymed":{"setId":"f423b484-2119-4c95-a0da-77bcd07303eb","title":"VITAMIN C BB BEAUTY BALM SHEER TINT SFP 30 (ZINC OXIDE) LOTION [ANDALOU NATURALS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SFP (likely referring to a ferric or iron-based formulation from Rockwell Medical) delivers bioavailable iron intravenously to correct iron deficiency and support red blood cell production. It is designed for patients who cannot tolerate or do not respond adequately to oral iron supplementation, particularly those with chronic kidney disease or other conditions causing iron-deficient anemia.","oneSentence":"SFP is an iron-based intravenous therapy that replenishes iron stores and stimulates erythropoiesis in patients with iron deficiency anemia.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:13.637Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Iron deficiency anemia in patients with chronic kidney disease"},{"name":"Iron deficiency anemia in patients intolerant to or unresponsive to oral iron"}]},"trialDetails":[{"nctId":"NCT07178821","phase":"NA","title":"Sling-Fiber Preservation POEM vs. Conventional POEM for Reducing Post-POEM GERD","status":"NOT_YET_RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-12-01","conditions":"Achalasia, Esophageal, GERD (Gastroesophageal Reflux Disease)","enrollment":120},{"nctId":"NCT04278924","phase":"PHASE2","title":"A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-11-09","conditions":"Primary Immune Thrombocytopenia","enrollment":41},{"nctId":"NCT06236100","phase":"NA","title":"Evaluating an Adverse Childhood Experience-Targeting Advocate Model of a Substance Use Prevention Program","status":"RECRUITING","sponsor":"RTI International","startDate":"2023-11-29","conditions":"Substance-Related Disorders, Adverse Childhood Experiences","enrollment":360},{"nctId":"NCT06805799","phase":"NA","title":"Stress Reactivity and Mother-Infant Cardiovascular Disease Risk","status":"NOT_YET_RECRUITING","sponsor":"Lifespan","startDate":"2025-03-15","conditions":"Maternal Health, Infant Health, Hypertension","enrollment":40},{"nctId":"NCT06528912","phase":"","title":"Standard Follow-up Program Neuro-oncology Patients (SFP Neuro-Oncology)","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2017-12-01","conditions":"Neurological Cancer","enrollment":10000},{"nctId":"NCT06429995","phase":"","title":"Standard Follow-up Program (SFP) for Breast Cancer Patients","status":"ENROLLING_BY_INVITATION","sponsor":"University Medical Center Groningen","startDate":"2008-01-01","conditions":"Breast Cancer","enrollment":10000},{"nctId":"NCT02435576","phase":"","title":"Standard Follow-up Program (SFP) for Head and Neck Cancer Patients","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2007-03","conditions":"Head and Neck Cancer","enrollment":10000},{"nctId":"NCT02733289","phase":"","title":"Standard Follow-up Program Cervix Cancer (SFP CERVIX)","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2015-06","conditions":"Cervical Cancer Radiation Complications","enrollment":10000},{"nctId":"NCT02421718","phase":"","title":"Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2013-03","conditions":"Lung Cancer","enrollment":10000},{"nctId":"NCT02454790","phase":"","title":"Standard Follow-Up Program (SFP) for Patients With Esophageal Cancer","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2014-09","conditions":"Esophageal Cancer","enrollment":10000},{"nctId":"NCT04222556","phase":"NA","title":"Evaluation of Thiwáhe Gluwáš'Akapi Substance Use Prevention Program","status":"UNKNOWN","sponsor":"University of Colorado, Denver","startDate":"2020-02-26","conditions":"Substance Use, Substance Abuse, Suicide","enrollment":552},{"nctId":"NCT03034187","phase":"","title":"Radiation-induced Toxicity in Prostate Cancer/ Standard-Follow-Up Program Prostate","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"1999-04","conditions":"Prostate Cancer","enrollment":10000},{"nctId":"NCT05117073","phase":"","title":"Risk Factors of Spontaneous Fungal Peritonitis in Cirrhotic Patients","status":"COMPLETED","sponsor":"Sohag University","startDate":"2021-09-01","conditions":"Spontanous Fungal Peritonitis","enrollment":100},{"nctId":"NCT04214327","phase":"NA","title":"Strengthening Families Program Online","status":"UNKNOWN","sponsor":"Strengthening Families Program LLC","startDate":"2022-12-15","conditions":"Substance Abuse","enrollment":480},{"nctId":"NCT04689932","phase":"PHASE4","title":"Triferic AVNU Infusion Via Freedom Pump During Hemodialysis","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2021-04-19","conditions":"End Stage Renal Disease","enrollment":12},{"nctId":"NCT02200770","phase":"PHASE2, PHASE3","title":"N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2015-04-01","conditions":"Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders","enrollment":231},{"nctId":"NCT05110768","phase":"PHASE2","title":"Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy","status":"UNKNOWN","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2021-11-30","conditions":"Iron Deficiency Anemia","enrollment":75},{"nctId":"NCT00858065","phase":"NA","title":"Adolescent Family-Based Alcohol Prevention","status":"COMPLETED","sponsor":"Pacific Institute for Research and Evaluation","startDate":"2005-04","conditions":"Alcohol Abuse, Drug Abuse","enrollment":1228},{"nctId":"NCT04409132","phase":"PHASE1, PHASE2","title":"Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2020-06-25","conditions":"End Stage Renal Disease","enrollment":23},{"nctId":"NCT04239391","phase":"PHASE3","title":"Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)","status":"UNKNOWN","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2020-09-01","conditions":"End Stage Renal Disease","enrollment":150},{"nctId":"NCT04042324","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2019-09-30","conditions":"End Stage Renal Disease","enrollment":12},{"nctId":"NCT00548249","phase":"PHASE2","title":"Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2007-08","conditions":"End-Stage Renal Disease (ESRD)","enrollment":131},{"nctId":"NCT03303144","phase":"PHASE1, PHASE2","title":"Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2017-10-01","conditions":"End Stage Renal Disease","enrollment":27},{"nctId":"NCT02905981","phase":"PHASE2","title":"Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol","status":"TERMINATED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2017-01-17","conditions":"Iron-Refractory Iron-Deficiency Anemia","enrollment":1},{"nctId":"NCT04484844","phase":"PHASE2, PHASE3","title":"Clinical Evaluation of Efficacy of Shield Force Plus Varnish VS Sodium Fluoride on Dentin Hypersensitivity","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-10","conditions":"Dentin Hypersensitivity, Dentin Desensitizing Agents","enrollment":68},{"nctId":"NCT02636049","phase":"PHASE1","title":"Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2015-10","conditions":"End Stage Renal Disease","enrollment":12},{"nctId":"NCT02909153","phase":"PHASE1","title":"Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2017-01","conditions":"Peritoneal Dialysis (PD), Anemia, Chronic Kidney Disease","enrollment":30},{"nctId":"NCT02767128","phase":"PHASE1","title":"Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2016-04","conditions":"Iron-refractory, Iron-deficiency Anemia (IRIDA)","enrollment":14},{"nctId":"NCT02739100","phase":"PHASE1","title":"Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2016-04","conditions":"End Stage Renal Disease","enrollment":13},{"nctId":"NCT03741465","phase":"NA","title":"A New Neuraxial Position Technique \" The Anatolian Sitting Position- Sitting Fetal Cross-legged\"","status":"COMPLETED","sponsor":"Yeditepe University","startDate":"2018-06-01","conditions":"Anesthesia, Conduction","enrollment":50},{"nctId":"NCT02595437","phase":"PHASE1, PHASE2","title":"Triferic Pediatric Pharmacokinetic Protocol","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2015-11-01","conditions":"End Stage Renal Disease","enrollment":22},{"nctId":"NCT01286012","phase":"PHASE2","title":"Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2011-01","conditions":"End Stage Renal Disease","enrollment":108},{"nctId":"NCT02995135","phase":"NA","title":"Sun Protection Factor Assay (341/2016)","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-01-03","conditions":"Sunscreening Agents","enrollment":10},{"nctId":"NCT01322347","phase":"PHASE3","title":"Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2011-04","conditions":"Renal Failure Chronic Requiring Hemodialysis","enrollment":294},{"nctId":"NCT01320202","phase":"PHASE3","title":"Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2011-03","conditions":"Renal Failure Chronic Requiring Hemodialysis","enrollment":305},{"nctId":"NCT02274792","phase":"PHASE4","title":"Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-01","conditions":"Plaque Psoriasis","enrollment":132},{"nctId":"NCT01503021","phase":"PHASE3","title":"Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2011-11","conditions":"End Stage Renal Disease, Chronic Kidney Disease","enrollment":718},{"nctId":"NCT00604565","phase":"NA","title":"Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients","status":"TERMINATED","sponsor":"Charles Drew University of Medicine and Science","startDate":"2008-01","conditions":"End Stage Renal Disease (ESRD)","enrollment":11},{"nctId":"NCT01894906","phase":"PHASE1, PHASE2","title":"Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2013-07","conditions":"Kidney Failure","enrollment":12},{"nctId":"NCT01920854","phase":"PHASE1","title":"A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2013-06","conditions":"Kidney Failure, Chronic Therapy; Hemodialysis","enrollment":48},{"nctId":"NCT02136875","phase":"PHASE4","title":"Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2008-07","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":37},{"nctId":"NCT01261182","phase":"NA","title":"Targeting School Feeding Programs at Vulnerable Sub-Groups","status":"COMPLETED","sponsor":"International Food Policy Research Institute","startDate":"","conditions":"Malnutrition, Cognition","enrollment":2083},{"nctId":"NCT00413452","phase":"PHASE3","title":"Etanercept SFP in RA Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12","conditions":"Rheumatoid Arthritis","enrollment":224},{"nctId":"NCT00439894","phase":"","title":"Ancillary Study to Protocol 20060104","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12","conditions":"Rheumatoid Arthritis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1422,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Soluble ferric pyrophosphate"],"phase":"marketed","status":"active","brandName":"SFP","genericName":"SFP","companyName":"Rockwell Medical Technologies, Inc.","companyId":"rockwell-medical-technologies-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SFP is an iron-based intravenous therapy that replenishes iron stores and stimulates erythropoiesis in patients with iron deficiency anemia. Used for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or unresponsive to oral iron.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}